|Bid||21.97 x 500|
|Ask||22.16 x 900|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||258.94|
|Expense Ratio (net)||0.30%|
Novartis expects to absorb the impact of generic competition and expects its 2017 sales to be in line with its 2016 revenue at a constant exchange rate.
Should you bet on European ETFs on an improving economy and corporate earnings?
Novartis's 2017 guidance is estimated to be broadly in line with its 2016 revenues at constant exchange rates.